Abstract Submissions
American Academy of Clinical Neuropsychology (AACN)
Annual Conference & Workshops on

"Excellence in Clinical Practice"

June 20-23, 2012
Renaissance Seattle Hotel - Seattle, Washington

SCIENTIFIC PROGRAM - CALL FOR POSTERS
DEADLINE: MARCH 1, 2012

Neuropsychologists, psychologists, students, interns, and residents are encouraged to submit their work for presentation.

The annual Edith Kaplan Trainee Research Award will be presented to the trainee voted to have the best poster presentation.


Submitter Contact Informationi

First Name: Last Name:

Institution:

Mailing Address:

Address (cont.):

City: State: Zip:

Country:

Email: Work Phone:

Cell Phone: Fax:

AACN Member:
Yes No

(membership not required)
  Is first author a student, intern or resident:
Yes No


Abstract Instructions

You will note the 200 word limit for your abstract. In addition to this limitation, please note the following instructions regarding your submissions:
  1. Only indicate the abstract as a student abstract if the student (or fellow) is a FIRST author.
  2. Submissions must include actual data, not data you plan to collect. Case studies are of course appropriate.
  3. Please refer to the below posted example abstract regarding style issues including the use of capitalization and acronyms in the title. Acronyms are acceptable in the text of the abstract. Some acronyms of more universally recognized assessment measures, procedures or disorders are Ok to use in the title. In the text they should still be spelled out fully for first use. The following list of measures, disorders, and procedures are the only ones that should be presented as acronyms in the title: all versions of WAIS, WMS, CVLT, MMPI, and HIV, TBI, PTSD, MRI, CT. It is acceptable to spell these out if you prefer, but please DO NOT assume acronyms with which you are familiar are universally understood. All others should be spelled out in the title and the first time they are used in the text.
  4. Please refrain from using section headers in the abstract (e.g., Methods, Results, etc.).
  5. Do not include credentials in the authors listing.
  6. Do not submit the same abstract twice – if you are unsure as to whether your submission went through, please wait it out then contact us directly if you remain unsure after 1-2 hours. Also, please check your spam/junkmail folder for the verification email.
Example Abstract:
NEAL, N., SCHWARZ, L., PLISKIN, N., BITYOU, L., & GROSSBERG, G.
The Utility of the Test of Memory Malingering in Patients with Dementia

The Test of Memory Malingering (TOMM) is one of the most well studied and frequently used symptom validity tests. However, few investigations have been conducted concerning its applicability in a dementia population. From these studies, conflicting data has emerged and its utility is unclear. The purpose of the present evaluation was to elucidate the role of the TOMM in evaluations of patients with dementia. The files of 21 patients diagnosed with dementia using the DSM-IV-TR criteria referred for neuropsychological evaluation were examined. Neurocognitive data included the Wechsler Test of Adult Reading (WTAR), the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the TOMM. The combined sample IQ was within the average range (WTAR predicted mean FSIQ=104.24, SD=13.67). The sample demonstrated overall mild impairment as assessed by the RBANS Total Index Score (mean=78.29, SD=17.920). TOMM performance was as follows: Trial 1 (mean=43.90, SD=7.20), Trial 2 (mean=47.57, SD=5.52), and Retention Trial (mean=31.50, SD=12.02). All trials of the TOMM correlated significantly with the RBANS Total Index (T1 r=0.72, T2 r=0.68, Retention r=1.00). Overall, results suggest that in individuals with more advanced dementia, the TOMM is likely not an appropriate measure of effort using the traditional cutoff of 45.


Abstract Submission Form

Poster Section: Adult Pediatric

Number of Authors:

                 First Name  Middle Initial  Last Name

Author #1:
Author #2:
Author #3:
Author #4:
Author #5:
Author #6:
Author #7:
Author #8:
Author #9:
Author #10:
Author #11:
Author #12:
Author #13:
Author #14:
Author #15:

Title:

Abstract:

ABSTRACT CLASSIFICATION: Please rank the two content areas which best categorize your abstract. Select a 1 for the primary categorization and 2 for the secondary categorization.

  1    2  1    2
Alzheimer's Disease HIV/AIDS
Attention Intellectual Functioning
Brain Tumors Language Disorders
Cerebrovascular Disease Learning Disabilities/ADHD
Cross Cultural Issues Medical Disorders
Dementia/Aging Memory
Demyelinating Disorders Movement Disorders
Developmental Neuroimaging
Epidemiology Neuropsychological Testing
Epilepsy Parkinson's Disease
Executive Functioning Psychiatric Disorders
Forensic Traumatic Brain Injury
Genetics Visuospatial Functions
Other:

AUTHOR PERMISSION TO PUBLISH ABSTRACT:
Corresponding author must authorize AACN the right to publish your abstract in The Clinical Neuropsychologist (TCN). In consideration of AACN reviewing and editing this abstract submission, the author hereby transfers, assigns or otherwise conveys on behalf of all authors ownership of this abstract to AACN in the event that this abstract is published. The author warrants that this abstract is original and holds AACN harmless for any and all defects or claims arising from its publication. I AGREE

CONFLICT OF INTEREST DECLARATION:
Corresponding author must complete.
1.a. Will your presentation include any commercial products or services?
         Yes No
(If No, skip to question 2)
1.b. If Yes, do you have a significant financial interest or other relationship with the manufacturer(s) of any of the products(s) or provider(s) of the products or services referenced in your presentation?
         Yes No (If No, skip to question 2)
     If Yes, please list the manufacturer(s) or provider(s) and describe the nature of the relationship(s):
    
2. Please list any and all sources of funding that supported the work described in your presentation:
    

Type OK in this box: (human verification)

UNDERSTANDING AND AGREEMENT:
I confirm that the information contained in this submission form is accurate. I understand and agree to the terms of this agreement.

AACN MEETING REGISTRATION INFORMATION: Corresponding authors must register for the meeting to be eligible to present their work. For questions, please contact Pamela McMurray via email: pamela.mcmurray@phci.org or by phone: 262-928-2652, or Gina Rehkemper via email: gina.rehkemper@phci.org or by phone: 262-928-7667.